{4-Chloro-3-[(2-chloro-4-{[(2S)-4-methyl-3,4-dihydro-2H-1,4-benzoxazin-2-yl]methoxy}benzoyl)amino]phenyl}acetic acid

ID: ALA1819622

Chembl Id: CHEMBL1819622

PubChem CID: 56665068

Max Phase: Preclinical

Molecular Formula: C25H22Cl2N2O5

Molecular Weight: 501.37

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  CN1C[C@@H](COc2ccc(C(=O)Nc3cc(CC(=O)O)ccc3Cl)c(Cl)c2)Oc2ccccc21

Standard InChI:  InChI=1S/C25H22Cl2N2O5/c1-29-13-17(34-23-5-3-2-4-22(23)29)14-33-16-7-8-18(20(27)12-16)25(32)28-21-10-15(11-24(30)31)6-9-19(21)26/h2-10,12,17H,11,13-14H2,1H3,(H,28,32)(H,30,31)/t17-/m0/s1

Standard InChI Key:  UQHKLJCYYLWRGF-KRWDZBQOSA-N

Associated Targets(Human)

PTGIR Tclin Prostanoid IP receptor (1280 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
TBXA2R Tclin Thromboxane A2 receptor (5717 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
PTGDR Tclin Prostanoid DP receptor (1356 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Ptger1 Prostanoid EP1 receptor (301 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Ptger2 Prostanoid EP2 receptor (304 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Ptger3 Prostanoid EP3 receptor (495 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Ptger4 Prostanoid EP4 receptor (338 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Ptgdr Prostanoid DP receptor (209 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Ptgfr Prostanoid FP receptor (188 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 501.37Molecular Weight (Monoisotopic): 500.0906AlogP: 5.15#Rotatable Bonds: 7
Polar Surface Area: 88.10Molecular Species: ACIDHBA: 5HBD: 2
#RO5 Violations: 2HBA (Lipinski): 7HBD (Lipinski): 2#RO5 Violations (Lipinski): 2
CX Acidic pKa: 3.44CX Basic pKa: 1.54CX LogP: 5.25CX LogD: 2.00
Aromatic Rings: 3Heavy Atoms: 34QED Weighted: 0.47Np Likeness Score: -1.00

References

1. Iwahashi M, Takahashi E, Tanaka M, Matsunaga Y, Okada Y, Matsumoto R, Nambu F, Nakai H, Toda M..  (2011)  Design and synthesis of new prostaglandin D₂ receptor antagonists.,  19  (18): [PMID:21885288] [10.1016/j.bmc.2011.08.007]
2. Iwahashi M, Naganawa A, Kinoshita A, Shimabukuro A, Nishiyama T, Ogawa S, Matsunaga Y, Tsukamoto K, Okada Y, Matsumoto R, Nambu F, Oumi R, Odagaki Y, Katagi J, Yano K, Tani K, Nakai H, Toda M..  (2011)  Discovery of new orally active prostaglandin D2 receptor antagonists.,  19  (22): [PMID:21982795] [10.1016/j.bmc.2011.08.065]

Source